257 related articles for article (PubMed ID: 28837162)
1. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.
Catucci I; Osorio A; Arver B; Neidhardt G; Bogliolo M; Zanardi F; Riboni M; Minardi S; Pujol R; Azzollini J; Peissel B; Manoukian S; De Vecchi G; Casola S; Hauke J; Richters L; Rhiem K; Schmutzler RK; Wallander K; Törngren T; Borg Å; Radice P; Surrallés J; Hahnen E; Ehrencrona H; Kvist A; Benitez J; Peterlongo P
Genet Med; 2018 Apr; 20(4):452-457. PubMed ID: 28837162
[TBL] [Abstract][Full Text] [Related]
2. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Keupp K; Hampp S; Hübbel A; Maringa M; Kostezka S; Rhiem K; Waha A; Wappenschmidt B; Pujol R; Surrallés J; Schmutzler RK; Wiesmüller L; Hahnen E
Mol Genet Genomic Med; 2019 Sep; 7(9):e863. PubMed ID: 31347298
[TBL] [Abstract][Full Text] [Related]
3. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia.
Bogliolo M; Bluteau D; Lespinasse J; Pujol R; Vasquez N; d'Enghien CD; Stoppa-Lyonnet D; Leblanc T; Soulier J; Surrallés J
Genet Med; 2018 Apr; 20(4):458-463. PubMed ID: 28837157
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
[TBL] [Abstract][Full Text] [Related]
5. Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics.
Bogliolo M; Surrallés J
Curr Opin Genet Dev; 2015 Aug; 33():32-40. PubMed ID: 26254775
[TBL] [Abstract][Full Text] [Related]
6. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
Sawyer SL; Tian L; Kähkönen M; Schwartzentruber J; Kircher M; ; ; Majewski J; Dyment DA; Innes AM; Boycott KM; Moreau LA; Moilanen JS; Greenberg RA
Cancer Discov; 2015 Feb; 5(2):135-42. PubMed ID: 25472942
[TBL] [Abstract][Full Text] [Related]
7. Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).
McReynolds LJ; Biswas K; Giri N; Sharan SK; Alter BP
Cancer Genet; 2021 Nov; 258-259():101-109. PubMed ID: 34687993
[TBL] [Abstract][Full Text] [Related]
8. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
Reid S; Schindler D; Hanenberg H; Barker K; Hanks S; Kalb R; Neveling K; Kelly P; Seal S; Freund M; Wurm M; Batish SD; Lach FP; Yetgin S; Neitzel H; Ariffin H; Tischkowitz M; Mathew CG; Auerbach AD; Rahman N
Nat Genet; 2007 Feb; 39(2):162-4. PubMed ID: 17200671
[TBL] [Abstract][Full Text] [Related]
9. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.
Virts EL; Jankowska A; Mackay C; Glaas MF; Wiek C; Kelich SL; Lottmann N; Kennedy FM; Marchal C; Lehnert E; Scharf RE; Dufour C; Lanciotti M; Farruggia P; Santoro A; Savasan S; Scheckenbach K; Schipper J; Wagenmann M; Lewis T; Leffak M; Farlow JL; Foroud TM; Honisch E; Niederacher D; Chakraborty SC; Vance GH; Pruss D; Timms KM; Lanchbury JS; Alpi AF; Hanenberg H
Hum Mol Genet; 2015 Sep; 24(18):5093-108. PubMed ID: 26085575
[TBL] [Abstract][Full Text] [Related]
10. The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction.
Vanni VS; Campo G; Cioffi R; Papaleo E; Salonia A; Viganò P; Lambertini M; Candiani M; Meirow D; Orvieto R
Hum Reprod Update; 2022 Feb; 28(2):296-311. PubMed ID: 35043201
[TBL] [Abstract][Full Text] [Related]
11. Fanconi-like anemia related to a FANCM mutation.
Encarnación JA; Cerezuela P; Español I; García MR; Manso C; De la Fuente I; Garrigós N; Viney A; Minguillon J; Surrallés J
Eur J Med Genet; 2022 Jan; 65(1):104399. PubMed ID: 34793962
[TBL] [Abstract][Full Text] [Related]
12. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
13. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
[TBL] [Abstract][Full Text] [Related]
14. Fanconi anemia: causes and consequences of genetic instability.
Kalb R; Neveling K; Nanda I; Schindler D; Hoehn H
Genome Dyn; 2006; 1():218-242. PubMed ID: 18724063
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
16. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Kiiski JI; Pelttari LM; Khan S; Freysteinsdottir ES; Reynisdottir I; Hart SN; Shimelis H; Vilske S; Kallioniemi A; Schleutker J; Leminen A; Bützow R; Blomqvist C; Barkardottir RB; Couch FJ; Aittomäki K; Nevanlinna H
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15172-7. PubMed ID: 25288723
[TBL] [Abstract][Full Text] [Related]
17. Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.
Freire BL; Homma TK; Funari MFA; Lerario AM; Leal AM; Velloso EDRP; Malaquias AC; Jorge AAL
Eur J Med Genet; 2018 Mar; 61(3):130-133. PubMed ID: 29133208
[TBL] [Abstract][Full Text] [Related]
18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
19. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
20. A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.
Bakker JL; Thirthagiri E; van Mil SE; Adank MA; Ikeda H; Verheul HM; Meijers-Heijboer H; de Winter JP; Sharan SK; Waisfisz Q
Hum Mutat; 2014 Apr; 35(4):442-6. PubMed ID: 24395671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
